Physician profile
Sharon Tasner
NPI 1821059163
$1,864.52
in general payments reported to CMS, 2019-2025
25 companies · $37.15 in 2025
The $37.15 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $657 · 2022: $945 · 2023: $193 · 2024: $32.22 · 2025: $37.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331.69 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $159.31 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $129.70 | 2021-2022 | |
| Glaxosmithkline, LLC. | $122.01 | 2021-2023 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.96 | 2021-2023 | Stiolto Respimat |
| Lilly USA, LLC | $113.20 | 2021-2023 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $109.55 | 2021-2022 | |
| Astellas Pharma US INC | $107.70 | 2021 | |
| Pfizer INC. | $92.44 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $79.53 | 2021-2022 | |
| Gilead Sciences, INC. | $75.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.04 | 2022 | |
| Merck Sharp & Dohme LLC | $66.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.14 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $42.83 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $27.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.16 | 2021-2022 | |
| Radius Health, INC. | $20.10 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.87 | 2023 | Quviviq |
| Ferring Pharmaceuticals INC. | $17.36 | 2023 | Rebyota |
| Amgen INC. | $17.32 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.76 | 2021 | |
| Esperion Therapeutics, INC. | $13.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.05 | 2021 | |
| Inogen, INC. | $8.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Tasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.